Cargando…

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease

INTRODUCTION: Clinical trials on preclinical Alzheimer’s disease are challenging because of the slow rate of disease progression. We use a simulation study to demonstrate that models of repeated cognitive assessments detect treatment effects more efficiently than models of time to progression. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dan, Iddi, Samuel, Aisen, Paul S., Thompson, Wesley K., Donohue, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656701/ https://www.ncbi.nlm.nih.gov/pubmed/31367671 http://dx.doi.org/10.1016/j.trci.2019.04.004

Ejemplares similares

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
por: Chen, Yun-Fei, et al.
Publicado: (2018)

Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes
por: Malpetti, Maura, et al.
Publicado: (2020)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study
por: Jutten, Roos J., et al.
Publicado: (2017)

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
por: Galasko, Douglas, et al.
Publicado: (2019)

Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis
por: Maserejian, Nancy, et al.
Publicado: (2021)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
por: Insel, Philip S, et al.
Publicado: (2020)

A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial
por: Bowman, Gene L., et al.
Publicado: (2019)

The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease
por: Burfeind, Kevin G., et al.
Publicado: (2017)

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
por: Weston, Philip S. J., et al.
Publicado: (2019)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease
por: Gelmont, David, et al.
Publicado: (2016)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
por: Meyer, Pierre-François, et al.
Publicado: (2019)

'Continuous learning is contagious'
por: Hylton, Preetee
Publicado: (2021)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Modeling Test and Treatment Strategies for Presymptomatic Alzheimer Disease
por: Burke, James F., et al.
Publicado: (2014)

Detection of presymptomatic Alzheimer's disease through breath biomarkers
por: Emam, Shadi, et al.
Publicado: (2020)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression
por: Firth, Nicholas C., et al.
Publicado: (2020)

Continuous Intravenous Milrinone Therapy in Pediatric Outpatients
por: Curley, Michelle, et al.
Publicado: (2017)

The continued importance of dental safeguarding during the pandemic
por: Foster, Mark
Publicado: (2021)

Telomere length associations with cognition depend on Alzheimer's disease biomarkers
por: Mahoney, Emily R., et al.
Publicado: (2019)

White matter hyperintensity topography in Alzheimer's disease and links to cognition
por: Garnier‐Crussard, Antoine, et al.
Publicado: (2021)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Wine glass size in England from 1700 to 2017: a measure of our time
por: Zupan, Zorana, et al.
Publicado: (2017)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease
por: Sousa, Amber, et al.
Publicado: (2015)

Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training
por: Teixeira, Camila Vieira Ligo, et al.
Publicado: (2018)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
por: Wittenberg, Raphael, et al.
Publicado: (2019)

Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer’s disease
por: Ryan, Natalie S., et al.
Publicado: (2013)

Public Willingness to Undergo Presymptomatic Genetic Testing for Alzheimer's Disease
por: Alanazy, Mohammed H., et al.
Publicado: (2019)

Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial
por: Hoscheidt, Siobhan, et al.
Publicado: (2021)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015)

Measuring informed consent capacity in an Alzheimer's disease clinical trial
por: Guarino, Peter D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c6b62bp6pcgcc6cd02766di74m